Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 284 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hematologic Tests Clear all
Completed Phase 2 Interventional Results available

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

NCT03030248
View directory record Official record
Conditions
Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 13, 2026, 9:33 AM EDT
Recruiting Phase 2 Interventional

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT02693535
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Interventions
Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Olaparib, Nivolumab and Ipilimumab, Abemaciclib, Talazoparib, Atezolizumab and Talazoparib, Tucatinib plus Trastuzumab Subcutaneous (SC), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
12 Years and older
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
174
States / cities
Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 13, 2026, 9:33 AM EDT
Completed Not applicable Interventional Results available

Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study

NCT06063603
View directory record Official record
Conditions
Chronic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Lymphoma, Malignant Solid Neoplasm, Multiple Myeloma
Interventions
Acupuncture Therapy, Cancer Pain Management, Cognitive Behavior Therapy, Discussion, Educational Intervention, Exercise, Interview, Massage Therapy, Mindfulness Relaxation, Pain Therapy, Palliative Therapy, Patient Navigation, Referral, Spiritual Therapy, Spiritual Care Referral, Survey Administration
Procedure · Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 13, 2026, 9:33 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Surface EMG Testing on Swallowing in EoE Patients

NCT07156357
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Surface Electromyography, Fiberoptic Endoscopic Evaluation of Swallowing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 13, 2026, 9:33 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

NCT03737981
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Obinutuzumab, Observation Activity, Venetoclax
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
65 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
857
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 555 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 13, 2026, 9:33 AM EDT
Completed No phase listed Observational

Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test

NCT03810144
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Vectra MBDA Test
Genetic
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Annapolis, Maryland • Baltimore, Maryland • Catonsville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 13, 2026, 9:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

NCT04439344
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Binimetinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 13, 2026, 9:33 AM EDT
Recruiting Not applicable Interventional

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

NCT07399977
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis
Interventions
MSK-ACCESS, ctDNA/VTE Risk Score:
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 13, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of Using Computerized Education to Increase Patients' Confidence in Their Ability to Be Screened for Colon Cancer

NCT00273585
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
Personally-tailored educational software program
Device
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2006 · Synced Sep 13, 2026, 9:33 AM EDT
Completed No phase listed Observational

Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients

NCT02035189
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Sep 13, 2026, 9:33 AM EDT
Completed No phase listed Observational

Addition of microRNA Blood Test to Lung Cancer Screening Low Dose CT

NCT03452514
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Hummingbird Diagnostics
Industry
Eligibility
55 Years to 80 Years
Enrollment
479 participants
Timeline
2017 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 13, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

NCT06326814
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
Humanized anti-Factor Bb monoclonal antibody, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 13, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

NCT03019666
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma, Indolent B Cell Lymphoma, Primary Mediastinal Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 13, 2026, 9:33 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

NCT06421636
View directory record Official record
Conditions
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Interventions
REGN7999, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 13, 2026, 9:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

NCT04439149
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
PI3K-beta Inhibitor GSK2636771
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 13, 2026, 9:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pulmonary Hypertension, Hypoxia and Sickle Cell Disease

NCT00495638
View directory record Official record
Conditions
Chuvash Polycythemia, Cerebrovascular Disease, Pulmonary Hypertension, Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
3 Years to 20 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 13, 2026, 9:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

NCT06390826
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Sunitinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 13, 2026, 9:33 AM EDT
Completed Phase 1 Interventional

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

NCT02831686
View directory record Official record
Conditions
Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma
Interventions
Selinexor, Ixazomib, Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 13, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Results available

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

NCT04277442
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Decitabine, Nivolumab, Venetoclax
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 13, 2026, 9:33 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

NCT04190550
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Interventions
Cytarabine, Idarubicin Hydrochloride, Navtemadlin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 13, 2026, 9:33 AM EDT
Recruiting Phase 3 Interventional

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

NCT07220915
View directory record Official record
Conditions
Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Interventions
Panzyga, 10% Intravenous Solution, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 13, 2026, 9:33 AM EDT
Completed Early Phase 1 Interventional

Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease

NCT01174940
View directory record Official record
Conditions
Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
Interventions
extracorporeal photopheresis
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 13, 2026, 9:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia

NCT01558076
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
8 Years to 21 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 13, 2026, 9:33 AM EDT
Completed No phase listed Observational

Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)

NCT03421626
View directory record Official record
Conditions
Leukemia, Myelogenous, Chronic
Interventions
Xpert BCR-ABL Ultra
Device
Lead sponsor
Cepheid
Industry
Eligibility
18 Years to 100 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Fort Lauderdale, Florida • Boise, Idaho • Columbia, South Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 13, 2026, 9:33 AM EDT